These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 25415807)

  • 1. Sodium zirconium cyclosilicate in hyperkalemia.
    Packham DK; Rasmussen HS; Lavin PT; El-Shahawy MA; Roger SD; Block G; Qunibi W; Pergola P; Singh B
    N Engl J Med; 2015 Jan; 372(3):222-31. PubMed ID: 25415807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.
    Anker SD; Kosiborod M; Zannad F; Piña IL; McCullough PA; Filippatos G; van der Meer P; Ponikowski P; Rasmussen HS; Lavin PT; Singh B; Yang A; Deedwania P
    Eur J Heart Fail; 2015 Oct; 17(10):1050-6. PubMed ID: 26011677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
    JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.
    Ash SR; Singh B; Lavin PT; Stavros F; Rasmussen HS
    Kidney Int; 2015 Aug; 88(2):404-11. PubMed ID: 25651363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HARMONIZE Asia: A Phase III Randomized Study to Investigate the Efficacy and Safety of Sodium Zirconium Cyclosilicate in Patients with Hyperkalemia in China.
    Liang X; Lu W; Yu X; Cheng H; He Q; Peng Q; Ni Z; Long G; Wang L; Chen W; Li R; Zhao J; Zhang Y; Lisovskaja V; Tang Z
    Clin Ther; 2024 Sep; 46(9):702-710. PubMed ID: 39112102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
    Rafique Z; Peacock WF; LoVecchio F; Levy PD
    Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
    Peacock WF; Rafique Z; Vishnevskiy K; Michelson E; Vishneva E; Zvereva T; Nahra R; Li D; Miller J
    Acad Emerg Med; 2020 Jun; 27(6):475-486. PubMed ID: 32149451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
    Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials.
    Amin AN; Menoyo J; Singh B; Kim CS
    BMC Nephrol; 2019 Dec; 20(1):440. PubMed ID: 31791288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.
    Packham DK; Kosiborod M
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):567-73. PubMed ID: 26998854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
    Roger SD; Lavin PT; Lerma EV; McCullough PA; Butler J; Spinowitz BS; von Haehling S; Kosiborod M; Zhao J; Fishbane S; Packham DK
    Nephrol Dial Transplant; 2021 Jan; 36(1):137-150. PubMed ID: 32030422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.
    Linder KE; Krawczynski MA; Laskey D
    Pharmacotherapy; 2016 Aug; 36(8):923-33. PubMed ID: 27393581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs to prevent and treat hyperkalemia.
    Lepage L; Desforges K; Lafrance JP
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis.
    Fu X; Zhang S; Gao F; Mao N
    Clin Nephrol; 2024 Oct; 102(4):223-231. PubMed ID: 38994592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.
    Roger SD; Spinowitz BS; Lerma EV; Singh B; Packham DK; Al-Shurbaji A; Kosiborod M
    Am J Nephrol; 2019; 50(6):473-480. PubMed ID: 31658466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.